Symptoms of human leishmaniasis range from subclinical to extensive systemic disease with splenomegaly, hepatomegaly, skin lesions, anemia and hyperglobulinemia, but the basis of this variation is unknown. Association of progression of the disease with Th2 lymphocyte response was reported in mice but not in humans. As most genetic studies in Leishmania major (L. major)-infected mice were restricted to skin lesions, we analyzed the symptomatology of leishmaniasis in mice by monitoring skin lesions, hepatomegaly, splenomegaly and seven immunological parameters. We detected and mapped 17 Leishmania major response (Lmr) gene loci that control the symptoms of infection. Surprisingly, the individual Lmr loci control 13 different combinations of pathological and immunological symptoms. Seven loci control both pathological and immunological parameters, 10 influence immunological parameters only. Moreover, the genetics of clinical symptoms is also very heterogeneous: loci Lmr13 and Lmr4 determine skin lesions only, Lmr5 and Lmr10 skin lesions and splenomegaly, Lmr14 and Lmr3 splenomegaly and hepatomegaly, Lmr3 (weakly) skin lesions, and Lmr15 hepatomegaly only. Only two immunological parameters, IgE and interferon-g serum levels, correlate partly with clinical manifestations. These findings extend the paradigm for the genetics of host response to infection to include numerous genes, each controlling a different set of organ-specific and systemic effects.
Introduction
Multicellular organisms are continually attacked by microbes. Effectiveness of the defense decides about life or death of the host. The Leishmania major infection in mice is one of the suitable models for study of interactions between pathogen and host.
Two million new cases of leishmaniasis are estimated to develop annualy, with 12 million people presently infected worldwide and several hundred million people at risk (www.who.int/leishmaniasis/burden/magnitude/). The disease is caused by protozoan parasites of genus Leishmania (Kinetoplastida: Trypanosomatidae) that infect mononuclear phagocytes of vertebrate host. 1 Consequences of infection range from none or only transient pathological changes to extensive systemic pathology. 2 Different species of Leishmania induce different symptoms, 3 but even the patients infected by the same species develop different symptoms and may vary in response to therapy. 4, 5 The causes of heterogeneity of clinical manifestations and their underlying immunological responses are not understood 6, 7 and are difficult to analyze in humans because of the impossibility to control environmental influences and genetic heterogeneity of human populations. However, many phenomena observed in human leishmaniases can be investigated in mouse models. The main aspects of the human lifethreatening visceral disease caused by L. donovani can be studied in mice infected by L. major 8 that therefore has been serving as a model of pathogenesis of this disease. In most mouse strains (e.g. C57BL/6, C3H, B10.D2, 129/ Sv and STS/A) L. major infection causes no or only temporary pathological changes, whereas in some strains (BALB/c, SWR/J) the parasites disseminate from the lymph nodes draining the site of the original cutaneous infection and cause a systemic disease affecting skin and visceral organs (reviewed in ). Progression or resolution of the disease have been attributed to the differences in responses of Th2 or Th1 CD4 þ lymphocytes, respectively. The 'non-healer' phenotype was reported to be associated with high level of interleukin (IL)-4 and low level of interferon (IFN)-g production 10 and low macrophage antiparasite activation by antigen-stimulated CD4 þ T lymphocytes. 11 Recently, concept of regulatory T cells that produce IL-10 was introduced to explain non-cure in mice exhibiting Th1 response. 12 An important role of non-T-cell compartments was also described. Interleukin-12 released by macrophages is a key factor in stimulation of Th1 response. 13 Interleukin-4 production from dendritic cells was surprisingly found to induce Th1 lymphocyte activity and resistance to L. major in BALB/c mice.
14 Neutrophils from the susceptible strain BALB/c stimulated Th2 responses, whereas neutrophils from the resistant strain C57BL/6 induced Th1 responses. 15 Experiments with chimeric BALB/c and C57BL/6 mice suggested the expression of 'curing genotype' both in T-cell and non-T-cell compartments, each of them being sufficient to confer cure. T cells from mice with 'non-curing genotype' mediated cure in C57BL/6 environment, despite the onset of Th2 cytokines production. 16 These and other complexities of experimental results suggest a need to supplement the classical Th1/Th2 paradigm to explain the genetic mechanisms of resistance to disease.
An insight into complex interactions between parasite and host can be obtained by genetic mapping, which can reveal host's genes controlling the outcome of infection, and their influence on different components of the immune response. Genetic mapping of susceptibility to L. major has been in most cases restricted to genes controlling development of skin lesions, [17] [18] [19] assuming that L. major-induced skin and visceral pathology correlate with each other 17 and hence are controlled by the same genes. To test this hypothesis and to elucidate the individual differences in manifestation of leishmaniasis, we decided to map not only the loci that control development of skin lesions, but also hepatomegaly, splenomegaly and a number of immunological parameters.
To analyze the multigenic control of response to L. major infection, we used a special tool for genetic analysis of complex biological traits, the recombinant congenic (RC) strains. 20, 21 The series of 20 CcS/Dem (CcS) RC strains is derived from two inbred strains, the background strain BALB/cHeA (BALB/c) and the donor strain STS/A (STS). Each of the 20 CcS strains contains a unique random set of about 12.5% genes from the resistant donor strain STS and 87.5% genes from the susceptible background strain BALB/c. As a consequence, the individual genes of the STS strain that control the resistance to leishmaniasis were randomly distributed into different RC strains. When infected by L. major, the CcS strains exhibited a continuous range of susceptibility (measured by the extent of skin lesions) demonstrating that the susceptibility is indeed multigenically controlled. 22 Our investigation whether the development of skin lesions in individual RC strains correlates with other pathological characteristics and immunological parameters led to surprising results: they have been correlated in some cases (skin lesion size correlated with splenomegaly, r ¼ 0.62, and with parasite load in lymph nodes, r ¼ 0.70) although there was no correlation between splenomegaly and load of parasites in spleen. Interleukin-4 and IFN-g levels were strongly correlated (r ¼ 0.74) and a similar correlation has been suggested in human leishmaniasis patients. 23 In most instances no significant correlations between different manifestations of infection were seen. The highest correlation between the clinical symptoms and immunological characteristics was between IgE levels and skin lesions (r ¼ 0.72). These data indicated that different pathological and immunological traits are largely controlled by different sets of genes that only partly overlap. 22 However, this notion needs to be rigorously examined by detection and mapping of individual genes controlling various symptoms of the disease. This evidence is given in the present paper.
We have selected for this analysis the RC strains CcS-5, -16 and -20 because they exhibit diverse symptomatology after infection. 24, 22 Previously, we have mapped in these strains several loci that control response to L. major. [25] [26] [27] In this paper, we present a complete genetic analysis of the whole set of pathological and immunological parameters in all three strains, including detection of four novel L. major response (Lmr) loci and description of additional effects of 10 previously detected Lmr loci. This comprehensive analysis revealed that different disease parameters are controlled by different sets of genes. Moreover, our tests revealed a very extensive functional heterogeneity of Lmr genes. The 17 Lmr loci detected in these tests affect 13 different combinations of organ pathology and immunological reactions. These findings suggest a novel paradigm for the genetics of resistance to infections, involving numerous loci, each controlling a different spectrum of organ-specific and systemic (immunological) effects.
Results
Functional heterogeneity of loci that control organ pathology and immunological parameters after L. major infection in the strain CcS-20 The F 2 hybrids between BALB/c and CcS-20 were infected with L. major and tested for clinical and immunological consequences of infection as described in Materials and methods. They were genotyped with microsatellite markers covering the STS-derived segments, that are located in this strain on 10 chromosomes. 21 Linkage analysis of different pathological and immunological parameters indicated three novel Lmr loci and novel functions for five previously mapped loci (Table 1 -single locus effects, Table 2 -gene interactions).
Splenomegaly is controlled by two loci. Lmr3 (chromosome 5) is linked to D5Mit55 and D5Mit114 (corr. P ¼ 0.0000646 and 0.00407, respectively). Its BALB/c allele is associated with a more severe splenomegaly. The effects of Lmr3 accounts for 5.29% of variance in splenomegaly in the cross. Lmr10 on chromosome 8 is linked to D8Mit125 and D8Mit54 (corr. P ¼ 0.00354 and 0.0000319, respectively). BALB/c allele determines more severe splenomegaly. The effects of Lmr10 accounts for 5.08% of variance in splenomegaly in the cross.
Skin lesions are also controlled by Lmr3 and Lmr10, but Lmr3, linked to D5Mit55 (corr. P ¼ 0.0136) exhibits a weaker influence on skin lesions than Lmr10 linked to D8Mit125 and D8Mit54 (corr. P ¼ 0.00000681 2.7% of genetic variance, and 0.00983, respectively). BALB/c allele of both Lmr3 and Lmr10 is associated with larger lesions. The effects of Lmr3 and Lmr10 account for 2.70 and 3.89%, respectively, of variance in skin lesions size. Only linkages significant at whole genome level are given. In order to obtain normal distribution required for analysis of variance, the following transformations were used: lesion size (mm 2 ) exhibited normal distribution without transformation; spleen to body weight ratio Â 1000-natural logarithm; IFN-g in serum (ng/ml)Ànatural logarithm of (value+1); TNF-a in serum (pg/ml)-power of 0.1 of the natural logarithm of (value+1); IL-6 in serum (ng/ml) -power of 0.977 of the natural logarithm of (value+1); [ Whereas, the symptoms of disease and the IgE levels were determined in all mice, the levels of cytokines and measurements of spontaneous proliferation could be not be performed on all mice. An unselected, random fraction of the mice had to be excluded due to unavailability of required amounts of serum and insufficient logistical capacity to prepare spleen cell cultures from all mice at the time of autopsy.
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Level of IFN-g is controlled by Lmr3 linked to D5Mit55 (corr. P ¼ 0.0484), that accounts for 5.22% of variance. Higher levels of IFN-g are associated with BALB/c allele. BALB/c homozygosity of Lmr3 (marked by D5Mit175) synergizes with STS homozygosity at Lmr17 (linked to D9Mit2) in increasing the IFN-g levels (corr. P ¼ 0.0046, Table 2 ). The effects of this interaction account for 6.63% of variance in level of IFN-g, and the remaining individual effects of Lmr3 at D5Mit175 and Lmr17 are negligible (1.36 and 0.07%, respectively).
Tumor necrosis factor (TNF)-a level in serum is influenced by Lmr17 (corr. P ¼ 0.0107). STS allele determines higher level of this cytokine in blood serum of infected mice. The effects of Lmr17 accounts for 6.78% of variance in TNF-a level in serum in the cross. Interleukin-6 level in serum is controlled by Lmr9 (chromosome 4) near D4Mit149 and by Lmr11 (chromosome 3) linked to D3Mit49 (corr. P ¼ 0.0182 and 0.0466, respectively). STS allele of both Lmr9 and Lmr11 is associated with higher IL-6 levels. The effects of Lmr9 and Lmr11 account for 14.36 and 13.98% of variance in serum IL-6 level, respectively.
Four loci influence spontaneous proliferation of spleen cells from infected mice in vitro. Leishmania major response 8 (chromosome 1) is linked with D1Mit17 (corr. P ¼ 0.00237) 0.98% of variance, Lmr3 (chromosome 5) with D5Mit143 (corr. P ¼ 0.00477), 0.88% of variance, and Lmr18 (chromosome 16) is linked with D16Mit7 (corr. P ¼ 0.00071). BALB/c alleles of Lmr8 and Lmr3 are associated with the high proliferation, whereas BALB/c allele of Lmr18 determines lower proliferative response. BALB/c homozygosity at Lmr18 synergizes with STS homozygosity at Lmr16 (marked by D2Mit52) in increasing proliferation (corr. P ¼ 0.0012, Table 2 ). The effects of this interaction accounts for 1.18% of variance, and the remaining individual effects of Lmr16 and Lmr18 are negligible (0.04 and 0.55%, respectively).
Loci that control cytokine levels in serum and spontaneous proliferation of spleen cells after L. major infection in the strain CcS-16 In addition to the previously reported loci controlling clinical manifestation in this strains, examination of immunological parameters in L. major-infected F 2 hybrids between CcS-16 and BALB/c lead to mapping of one novel Lmr locus and revealed novel functions of five Lmr loci (Table 3 -single locus effects, Table 4 -gene interactions), that we previously found to control skin and/or visceral pathology 27 and/or IgE level in serum. 26 Interferon-g level in serum is controlled by two loci with opposite effects. STS allele of Lmr14 on chromosome 2 linked to D2Mit102 is associated with higher level of IFN-g in serum (corr. P ¼ 0.0325) and accounts for 5.74% of variance, whereas STS allele of Lmr15 (chromosome 11), linked to D11Mit15 determines low level of IFN-g (corr. P ¼ 0.0161) and this locus accounts for 10.83% of variance. Interleukin-4 level is controlled by Lmr12 on chromosome 16, which is linked to D16Mit126 (corr. P ¼ 0.0484). It accounts for 11.10% of variance in the cross. Its STS allele is associated with higher level of IL-4 in serum (Table 3) .
Interleukin-12 level in serum (Table 4) is influenced by interaction of Lmr14 (chromosome 2) linked to D2Mit102 with Lmr5 (chromosome 10) marked by D10Mit103. Highest level is observed in STS homozygotes at both loci (corr. P ¼ 0.0133). This interaction accounts for 8.65% Table 2 Interactions between loci that control immunological parameters in Leishmania major-infected F2 hybrids between CcS-20 and The numbers give natural logarithm of (IFN-g in serum (ng/ml)+1); [ Tumor necrosis factor-a in serum is controlled in CcS-16 by three loci that have no apparent individual effect on this parameter, but their influence results from gene interactions. BALB/c homozygosity at Lmr14 (marked by D2Mit283) in combination with BALB/c homozygosity at Lmr12 (linked to D16Mit126) increases TNF-a level. Lower TNF-a levels are observed in STS homozygotes at both Lmr14 and Lmr12 (corr. P ¼ 0.00238). The interaction between these loci accounts for 6.03% of total variance, the individual effects of these loci are minimal (1.22 and 0.5%, respectively). Interaction of STS homozygosity at Lmr14 with STS homozygosity at Lmr13 (near D18Mit49) determines low level of TNF-a in serum (corr. P ¼ 0.0261). This interaction accounts for 7.24% of variance, the individual effects of Lmr14 and Lmr13 are very small (1.06 and 0.17%, respectively).
Three loci control spontaneous proliferation of spleen cell from infected mice in vitro. BALB/c allele at Lmr14 (linked to D2Mit389) determines higher proliferation (corr. P ¼ 0.0189) ( Table 3) . BALB/c homozygosity at Lmr19 (marked by D10Mit67) synergizes with STS homozygosity at Lmr12 (near D16Mit126) in increasing proliferative response (corr. P ¼ 0.00142) ( Table 4 ). The effects of Lmr14 account for 5.11% of variance, the interaction Lmr19-Lmr12 for 8.53% of variance, and the remaining effects of these two loci are minimal -0.69 and 1.03%, respectively. Table 5 shows summary of the detected effects of Lmr loci. We have grouped the identified Lmr loci according to their effects on organ pathology (skin lesions, splenomegaly, hepatomegaly) and systemic immunological parameters (IgE, IFN-g, IL-12, TNF-a, IL-4 and IL-6 levels in serum and spontaneous proliferation of lymphocytes from infected mice). The 17 Lmr loci affect 13 different combinations of pathological symptoms and immunological reactions, the latter being frequently influenced by gene interactions.
Functional heterogeneity of Leishmania major response effects
Only two combinations of phenotypic effects were controlled by more than one Lmr locus: IgE and IL-6 levels in serum are controlled by both Lmr11 (in interaction with Lmr8) and Lmr9, and spontaneous proliferation of lymphocytes from infected mice is controlled by Lmr16, Lmr19, Lmr18 and Lmr7 (Lmr16 in interaction with Lmr18, Lmr19 in interaction with Lmr12, Lmr18 in interaction with Lmr16 and also alone, and Lmr7 alone).
Seven Lmr loci control both pathological and immunological parameters, whereas 10 loci influence immunological parameters only. A very pronounced functional heterogeneity was observed in genetic influences on skin and visceral pathology: Lmr13 and Lmr4 determine skin lesions only, Lmr5 and Lmr10 control skin lesions and splenomegaly, Lmr14 controls splenomegaly and hepatomegaly (but not skin lesions) and Lmr15 determines hepatomegaly only. Lmr3 carried by CcS-20 controls splenomegaly and skin lesions, whereas Lmr3 carried by CcS-5 influences splenomegaly and hepatomegaly. Only two immunological parameters appeared to correlate with clinical symptoms: five out of seven 'pathology' loci controlled also the IgE levels in serum and all loci Table 3 Significant linkages of immunological parameters in Leishmania major-infected 
Discussion
The course of infection with L. major, its pathogenetic pathways, and its ultimate outcome are profoundly influenced by the genome of the infected host. Similarly as the molecular tools used by different species of Leishmania to subvert host's defences have been used to Only linkages significant at whole genome level are given. In order to obtain normal distribution required for analysis of variance, the following transformations were used: IL-12 level in serum (ng/ml)Àpower of 0.65 of the natural logarithm of value; TNF-a in serum (pg/ ml)Àpower of 0.4 of logarithm of (value+1); [ 
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225 identify the components of the immune system that they target, 3 the identification of host's genes responsible for the specific symptoms of the disease will contribute to the understanding of mechanisms of its pathogenesis. In addition, it will provide description of individual predisposition to specific symptoms of disease and its probable course. We have shown here that the development of individual symptoms of disease is controlled by different subsets of host's genes.
In this and previous [25] [26] [27] papers we have defined the Lmr loci that control pathology and immunological reactions in the highly resistant strain CcS-5, the relatively resistant strain CcS-20, and the highly susceptible strain CcS-16. In this way we obtained comprehensive information about the genetic control of 10 pathological and immunological phenotypes that are part of the multifaceted response to L. major infection in the three strains. Due to high-resolution power of the RC system, this resulted in mapping of 17 loci: Lmr3-Lmr19. Table 5 summarizes their functional effects in different strains and Figure 1 indicates their chromosomal positions. These loci exert their effects either as a single gene, or in interactions. The relative sizes of these effects are expressed as proportion (percent) of total variance in the tested cross. In the new linkages reported here, the percentage of explained variance is within the range usually observed for loci involved in multigenic inheritance. An exception are the three loci that control the rate of spontaneous proliferation in (BALB/c Â CcS-20)F 2 hybrids. Their contribution to total variance is very low -around 1-1.5%. This is possibly due to high total level of variance. Two of these loci, Lmr3 and Lmr8 have been described previously and in this paper to affect other components of the response to L. major infection as well. Leishmania major response 3 contributions to the total variance of skin lesion size, splenomegaly, and serum levels of IFN-g are within the range of 2.7-5.3%. Moreover, this locus as well as Lmr8 have been detected also in previous experiments. 25, 26 Lmr18 is a novel locus. In spite of its low contribution to total variance its alleles have very significant phenotypic effects on spontaneous proliferation (P corr.o0.0055), mice homozygous for BALB/c allele exhibiting about twofold proliferation rate than mice with other genotypes. When evaluating the contribution of individual loci to the total phenotypic variation it is necessary to take into consideration that the total variation of different phenotypes in the same cross is likely to be different, as well as the total variation 
CcS-16
The table includes also results described in Lipoldová et al., 25 Badalová et al. 26 and Vladimirov et al. 27 Loci are sorted according their influence on organ pathology (skin lesions, splenomegaly, hepatomegaly) and systemic immune response (IgE, IFN-g, IL-12, TNF-a, IL-4, IL-6 levels in serum and spontaneous proliferation of lymphocytes from infected mice). Colors indicate phenotypic effects of alleles: Blue -C4S, pink -C oS, yellow -interaction, NT -not tested.
of the same phenotype in two different crosses. Therefore, the values of contribution of individual loci should be considered within the context of these limitations.
Our data show that interaction of mice with L. major parasites is complex and involves many genes and responses. Only a part -seven of the 17 Lmr loci -control both the disease manifestations in organs and systemic immunological reactions. These are the 'pathology loci' and in the tested genetic background they are the most important loci for determination of consequences of infection. We have also found 10 Lmr loci that control only systemic immunological parameters. They can be considered 'immunological loci.' Their effects often depend on gene interactions. These two types of loci reflect the complexity of the interplay between the host and the pathogen. Some loci directly modify the parasiteassociated pathology, others may reflect secondary consequences of primary responses. While some secondary responses are likely to modify the pathogen-induced disease, others may be by-products of the host's response without any effect on the disease. It also cannot be ruled out that in a different genetic background some of the 'immunological loci' could influence organ pathology. Lmr6 on chromosome 11, detected in the cross involving genomes of BALB/c and STS, controls only IL-4 level in serum; 25 in the crosses between BALB/c and B10.D2 a locus in approximately same location determines skin lesions (influence on other traits has not been tested). 17 However, this effect could also be caused by another locus close to Lmr6 or to a different function of the Lmr6 allele of B10.D2.
The observed multiple effects of some Lmr loci suggest that such loci might represent complexes of two or more closely linked Lmr genes. There are some indications of it in results of mapping of Lmr5 and Lmr3. The genomic segments on chromosome 10 containing Lmr5 that we have mapped in the cross between BALB/c and CcS-5 and in the cross between BALB/c and CcS-16 are different but overlap (Figure 1) . The STS-derived segment in CcS-5 is 28 cM long and controls skin lesions, splenomegaly, IgE, IFN-g and IL-12 levels in serum. STSderived segment carried by CcS-16 is only 3 cM long and controls IgE level and in interaction with Lmr14 on chromosome 2 also IL-12 level in serum. It is therefore probable that there are two genes in Lmr5 locus: one situated in the more centromeric part of the chromosome controls skin lesions, splenomegaly and IFN-g level in serum, whereas the more telomeric gene controls IgE and IL-12 level in serum. 
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A similarly complex situation is observed in Lmr3 on chromosome 5. We have also mapped this locus in two crosses: between BALB/c and CcS-5 and between BALB/c and CcS-20. The STS-derived segment carried by CcS-20 is longer À 33 cM (from 28 to 61 cM), whereas CcS-5 carries only part of this region: from 34 to 44 cM. Leishmania major response 3 in both CcS-5 and CcS-20 controls splenomegaly, IgE and IFN-g levels in serum and has a weak effect on development of skin lesions, but Lmr3 carried by CcS-5 controls also hepatomegaly, but has no influence on skin pathology. Possible explanation is that the pertinent chromosomal segment carried by CcS-20 might contain two genes with opposite effects which mask each other, or that genes might behave differently on different genetic backgrounds. 28 Several Lmr loci may be related to quantitative trait loci (QTLs) controlling certain immunologicaly relevant traits, because they co-map with other immunological functional polymorphisms. Leishmania major response 3, Lmr8 and Lmr12 colocalize with loci influencing ConAinduced production of IL-4 or IL-10 in lymphocytes of uninfected mice, 29 suggesting that these loci may be primarily involved in regulation of lymphocyte function. Some Lmr genes may control susceptibility to several pathogens, similarly as Nramp1 (natural resistance-associated protein 1)/Slc11a1 (solute carrier family 11, member 1) 30 or sst1 (super susceptibility to tuberculosis 1)/Ipr1 (intracellular pathogen resistance 1). 31 This is suggested by colocalization of QTLs influencing response to other infectious agents such as mouse pox, 32 Mycobacterium tuberculosis, 33 Trypanosoma congolense, 34 Leishmania donovani, 35 Borrelia burgdorferi, 36 Salmonella typhimurium, [37] [38] [39] Listeria monocytogenes 40 and Trypanosoma cruzi 41 with several Lmr loci ( Table 6 ). The results of this comprehensive genetic study extend the present understanding of genetics of leishmaniasis, and by extrapolation also of several other infectious diseases. They show that the host response to infection is controlled by a large number of genes that act as QTLs. Presently we mapped 17 such loci for L. major infection. Most of them control several phenotypic traits associated with infection. Importantly, we have observed the heterogeneity of gene functions in three different crosses. This indicates that the functional heterogeneity of these genes is a common phenomenon rather than an exception. We do not yet know whether all the different effects of a single Lmr locus are controlled by the same gene, or whether they are controlled separately by several closely linked genes. This question is being presently analyzed by recombinational analysis. Probably, both types of complexity will be found. Although the spectrum of symptoms affected by individual loci need not be absolute and can be possibly modified by the external factors like intensity of infection, 42 concomitant infection, or general condition of the organism, as well as genetic background, their clear-cut functional heterogeneity that Conspicuous is the great variety of phenotypic effects of Lmr loci. In fact, the 17 Lmr loci control 13 different combinations of phenotypic effects (Table 5 ) and only two combinations of effects are controlled by more than one Lmr locus: both Lmr11 and Lmr 9 control IgE and IL-6 serum levels, and Lmr7, -16, -18 and -19 have all the same single effect -level of spontaneous lymphocyte proliferation in infected mice. However, it is possible that when additional parameters will be tested, they will differentiate between the presently functionally undistinguishable effects of at least some of these loci. Our mapping results may provide also suggestions about mechanism of the disease. Multiple genes with multiple functions suggest a network of different mechanisms operating on different cellular compartments. The decision between healing and disease is a result of relationships between alleles that control alleviation and aggravation of disease symptoms. This also means that in the resistant strain STS the responses, which are controlled by Lmr12, 13 and 14, might aggravate the pathology.
The present results also indicate a potentially important analogy to the leishmaniasis in humans. Similarly to the RC strains that carry each a different subset of Lmr genes predisposing them to a certain quantitatively and qualitatively characteristic disease phenotype, the humans also likely carry different subsets of Lmrhomologous genes. Such genes will likely predispose them to healing or to disease, and in the latter case they can also modify the type of clinical manifestations and their intensity. The identification of these genes would help to detect the individuals with high disease susceptibility or with tendency to generalized disease. As the human populations are heterogeneous both genetically, in exposure to infection, and in other important factors (nutrition, presence of other infections), direct detection and identification of Lmr genes in humans may be extremely difficult. The use of genetically defined mice and standardized infection protocols make this task more feasible. After the Lmr genes have been mapped, their molecular identification can be achieved in the same way as with other disease QTLs (see e.g. molecular identification of cancer susceptibility QTLs by Ruivenkamp et al. 43 and Zhang et al.
44
). This includes mapping of Lmr loci to very short chromosomal regions and detection of functionally relevant polymorphisms in expression or structure of genes in these short regions, followed by functional confirmation in vitro or by germline modification. Table 6 lists the potential candidate genes for a number of Lmr loci. [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] We have been producing congenic mouse strains that carry each Lmr locus in a very short segment of chromosome. The testing of these strains will restrict the present number of the candidate genes to the most likely ones and some presently unsuspected candidates may be added. This step will precede the final molecular identification of the Lmr genes. Their human homologues can then be readily identified and their role in infection tested. The identification of the mouse and human Lmr genes can lead to the understanding of the prevalent pathogenetic pathways associated with different Lmr genotypes with ensuing possibilities of individual therapy, as well as provide novel potential targets for pharmacotherapy. 
Materials and methods
Mice
Mice of the background parental strain BALB/c and the RC strains CcS-16 and CcS-20 were from the breeding colony of P Demant. When used for these experiments, the RC strains were in the generation 37 of inbreeding and therefore highly homozygous. The parts of CcS-16 and CcS-20 genomes inherited from the BALB/c or STS parents were defined. 21 Female F 2 hybrids between CcS-16 and BALB/c (age 14-17 weeks at the time of infection) and female F 2 hybrids between CcS-20 and BALB/c (age 9-14 weeks) were produced at the Institute of Molecular Genetics. Each cross was tested in four independent experimental groups.
Parasites
Leishmania major LV 561 (MHOM/IL/67/LRC-L137 JERICHO II) was maintained in rump lesions of BALB/c females. Amastigotes were transformed to promastigotes using SNB-9. 62 10 7 promastigotes from 6-to 7-day-old subculture 2 were inoculated in 50 ml sterile saline s.c. into mouse rump.
Disease phenotype
The size of the primary skin lesions was measured weekly using a Vernier caliper gauge. The mice were killed 8 weeks after infection and body, spleen and liver weights were recorded.
Cytokine and IgE levels
IgE, IFN-g, IL-12, TNF-a, IL-4 and IL-6 levels in serum were determined using the primary and secondary monoclonal antibodies (IgE: R3572, R3592; IFN-g: R46A2, XMG1.2; IL-12: Red-T and G297-298, C17.8; TNF-a: MP6-XT22, polyclonal rabbit IgG; IL-4: BVD41D11, BVD624G2; IL-6: MP5-20F3, MP-532C11) and standards from Pharmingen (San Diego, CA, USA) (IgE3, recombinant mouse IFN-g, mIL-12 p70 heterodimer, mTNF-a, mIL-4 and mIL-6). The enzyme-linked immunoabsorbant assay (ELISA) was performed as recommended by Pharmingen. The cytokine and IgE levels were estimated using the curve fitter program KIM-E.
Lymphocyte proliferation Spleen cells (10 5 cells per well from F 2 hybrids between CcS-20 and BALB/c; 0.8 Â 10 6 cells per well from F 2 between CcS-16 and BALB/c) were incubated in 200 ml of complete RPMI 1640 medium in 96-well tissue culture plates (Nunc, Roskilde, Denmark) as described elsewhere. 63 Genotyping of F 2 mice by PCR DNA was isolated from tails using a standard proteinase procedure. The strains CcS-20 and -16 differ from BALB/c at STS derived segments on 10 and nine chromosomes, respectively (Stassen et al. 21 and unpublished results). These differential segments were typed in the F 2 hybrid mice between CcS-20 and BALB/c using 26 microsatellite markers (Research Genetics, Huntsville, FL, USA): D1Mit14, D1Mit227, D1Mit17, D2Mit52, D2Mit148, D2Mit74, D3Mit25, D3Mit49, D3Mit11, D4Mit149, D5Mit55, D5Mit114, D5Mit175, D5Mit63, D5Mit143, D6Mit52, D6Mit58, D8Mit125, D8Mit54, D9Mit90, D9Mit2, D14Mit129, D14Mit170, D16Mit15, D16Mit19 and D16Mit7. For the analysis of the F 2 hybrid mice between CcS-16 and BALB/c 23 microsatellite markers were used (Research Genetics, Huntsville, FL, USA): D2Mit156, D2Mit389, D2Mit102, D2Nds3, D2Mit283, D2Mit51, D3Mit25, D3Mit11, D4Mit153, D6Mit48, D6Mit320, D10Mit67, D10Mit103, D11Mit139, D11Mit242, D11Mit37, D16Mit126, D17Mit38, D17Mit130, D18Mit120, D18Mit35, D18Mit40 and D18Mit49. In both crosses, the maximum distance between any two markers in the chromosomal segments derived from the strain STS or from the nearest BALB/c derived markers was 20 cM, so distance of any mapped locus to the nearest marker could not exceed 10 cM. The PCR genotyping was performed as described elsewhere. 64 
Statistical analysis
The role of genetic factors in control of the tested pathological and immunological symptoms was examined with ANOVA (NCSS, Kaysville, UT, USA). The effect of each marker and of interaction between markers on skin lesions and splenomegaly was also tested by the PROC GLM (general linear model) statement of the SAS 6.12 for Windows. Marker, gender and age were fixed factors and the experiment was considered a random parameter. In order to obtain normal distribution of the analyzed parameters, the obtained values were transformed as shown in the legends of tables. The percent variance accounted for by a QTL and that accounted for by the interaction terms has been calculated from the regressions of SS terms of ANOVA models. Markers and interactions with Po0.05 were combined in a single comparison. For each independent variable the partial R 
